Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas S Berry

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Statistical Analysis and Data Mining|March 5, 2021
A clustering method for graphical handwriting components and statistical writership analysisAmy M Crawford, Nicholas S Berry, Alicia L Carriquiry
Clinical Trials (London, England)|August 22, 2022
The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trialsBenjamin R Saville, Donald A Berry, Nicholas S Berry, et al.
Clinical Trials (London, England)|July 5, 2022
An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolismSharon D Yeatts, Lydia D Foster, William G Barsan, et al.
Clinical Trials (London, England)|December 21, 2022
Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet StudyNicole D Zantek, Marie E Steiner, John M VanBuren, et al.
Plos One|July 30, 2021
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19Donald A Berry, Andrew Ip, Brett E Lewis, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
Plos One|August 14, 2020
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational studyAndrew Ip, Donald A Berry, Eric Hansen, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Statistical Analysis and Data Mining|March 5, 2021
A clustering method for graphical handwriting components and statistical writership analysisAmy M Crawford, Nicholas S Berry, Alicia L Carriquiry
Clinical Trials (London, England)|August 22, 2022
The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trialsBenjamin R Saville, Donald A Berry, Nicholas S Berry, et al.
Clinical Trials (London, England)|July 5, 2022
An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolismSharon D Yeatts, Lydia D Foster, William G Barsan, et al.
Clinical Trials (London, England)|December 21, 2022
Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet StudyNicole D Zantek, Marie E Steiner, John M VanBuren, et al.
Plos One|July 30, 2021
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19Donald A Berry, Andrew Ip, Brett E Lewis, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
Plos One|August 14, 2020
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational studyAndrew Ip, Donald A Berry, Eric Hansen, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 1